Market Scenario

Global Absorbable Heart Stent Market generated revenue of US$ 307.1 million in 2022 and is estimated to reach a valuation of US$ 822.7 million by 2031 at a CAGR of 12.02% during the forecast period, 2023–2031.

The demand for absorbable cardiac stents is expected to grow significantly, driven by several key factors. Firstly, the rise in the prevalence of coronary artery disease and the corresponding increase in the proportion of percutaneous coronary intervention (PCI) procedures is expected to drive the market growth. Moreover, the market for absorbable heart stents is expected to expand due to rising government initiatives for healthcare reform and a growing number of patients with chronic  illnesses.

In particular, the incidence of peripheral arterial disease (PAD) and coronary artery disease (CAD) is expected to increase, which would lead to a rise in demand for absorbable heart stents. For example, according to the American Academy of Cardiology, the number of individuals worldwide with PAD increased from 164 million in 2000 to 256 million in 2022. With 17.9million deaths per year, cardiovascular diseases (CVDs) are the leading cause of death worldwide. Coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other illnesses are among the categories of heart and blood vessel disorders known as CVDs. Heart attacks and strokes account for more than four out of every five CVD deaths, and one-third of these deaths happen before the age of 70. 

Furthermore, greater awareness of the benefits of absorbable cardiac stents is expected to boost adoption and demand during the projection period, thereby contributing to market growth. However, it is worth noting that the high cost of absorbable stents could act as a limiting factor on the market's growth over the forecast period.

To Get more Insights,  Request A Free Sample 

Key Dynamics of Absorbable Heart Stent Market

Drivers

Increasing Prevalence of Cardiovascular Diseases 

Cardiovascular diseases continue to pose a critical public health issue, with a rising incidence globally. This trend can be attributed to various factors such as changing lifestyles, increasing obesity rates, and alcoholism. In 2019, CVDs accounted for almost a third of all deaths worldwide, with over 18 million deaths reported, including 8.9 million deaths of women and 9.6 million deaths of men. Shockingly, more than 6 million of these fatalities occurred in people aged between 30 to 70, with the most affected countries being China, India, Russia, the US, and Indonesia.

In the United States, CVDs remain the leading cause of fatalities, with about 836,546 deaths reported in 2018. This means that one in three fatalities in the country in 2018 were caused by CVDs. Heart failure and stroke are the second and third major causes of death in the US, respectively, with nearly 2,300 Americans dying every day because of cardiovascular diseases (CVDs). To lower the death rates from cardiac disorders, there is an increase in demand for absorbable heart stents as a result.

Restraint

Complexities in Manufacturing Processes

Despite the significant potential of bioabsorbable stents, the manufacturing process is complex and challenging. The ideal bioabsorbable stent must possess adequate radial strength for the right amount of time, have thin struts, function as a drug delivery system, and degrade acceptably. The primary drawback of these stents is the increased risk of device thrombosis, which endangers patient safety. Previous studies have shown that bioabsorbable stents have a device thrombosis rate of 2.1% at six months, which is a 20% increase in mortality risk for patients.

Trend

Increase in Demand for Minimally Invasive Surgeries

Minimally invasive surgeries offer several advantages such as reduced discomfort, fewer complications, and shorter hospital stays. These surgical techniques are now widely used in cardiothoracic surgery, gastroenterology, gynaecological surgery, cardiac surgery, paediatric surgery, urogynecology and pelvic reconstructive surgery, and urological surgery. The World Health Organization (WHO) estimates that chronic diseases, including cardiovascular disease, will cause 1.5 million deaths in 2021. Chronic illnesses, in general, cause 71% of all deaths globally, with chronic disease deaths estimated at 41 million annually. The market for minimally invasive surgery is expected to grow as laparoscopic surgery becomes increasingly popular.

Market Segmentation

By Material

By material type, biopolymers have gained immense popularity for medical applications due to their biocompatibility and biodegradability. Wherein, absorbable heart stents are a relatively new type of medical device made from biopolymers.

The traditional metal stents used in cardiac surgeries can cause long-term complications, such as inflammation and restenosis (the re-narrowing of the coronary artery). In line with this, absorbable stents are designed to dissolve over time, leaving behind only the healed artery. Biopolymers are used in the production of absorbable heart stents due to their biocompatibility and biodegradability.

One example of a biopolymer used in absorbable heart stents is polylactic acid (PLA). PLA is a biodegradable polymer derived from lactic acid, which is naturally produced in the body. When PLA is used in an absorbable heart stent, it gradually degrades over time, releasing drugs that prevent restenosis and inflammation. Other biopolymers that are used in absorbable heart stents include polyglycolic acid (PGA) and polycaprolactone (PCL). PGA is a biodegradable polymer that is derived from glycolic acid, and PCL is a biodegradable polyester that is derived from caprolactone. Both PGA and PCL are biocompatible and degrade slowly over time, making them ideal for use in absorbable heart stents.

By Absorption Rate 

Fast absorption heart stents are holding the largest revenue share in the global absorbable heart stent market due to several factors. Most of surgeons are preferring this product as it provides an optimal balance between strength and degradation time and maintains its structural integrity long enough to support the vessel wall during the healing process, but then degrade rapidly to allow for complete resorption. This means that patients are less likely to experience complications such as inflammation and restenosis.

In addition to this, fast absorption heart stents are made from biopolymers that are optimized for rapid degradation. These biopolymers include polylactic acid (PLA), polyglycolic acid (PGA), and polycaprolactone (PCL), which have been extensively studied and have demonstrated excellent biocompatibility and biodegradability in clinical trials. The segmental growth is further supported by easier manufacturing process compared to traditional metal stents. 

Finally, fast absorption heart stents have been approved for use in several countries around the world, including the United States, Europe, and Japan. This has led to increased demand for these stents, which in turn has driven market growth and revenue.

By Application 

By application, Coronary heart disease is holding the largest market share since it emerged as the leading cause of morbidity and mortality worldwide, and the demand for effective treatments for this condition has led to an increase in the consumption of absorbable heart stents. Several factors are driving the demand for absorbable heart stents in the treatment of CHD. One of the main factors is the high incidence of CHD, particularly in aging populations. The increasing prevalence of risk factors such as obesity, diabetes, and hypertension is also contributing to the rising demand for effective treatments for CHD.

According to the World Health Organization (WHO), CHD is responsible for 9.4 million deaths worldwide each year. In the United States alone, CHD affects an estimated 18.2 million adults, or 6.7% of the population.

Another driver of the demand for absorbable heart stents is the growing preference for minimally invasive procedures. Absorbable heart stents are less invasive than traditional metal stents, which require open-heart surgery. Patients also prefer absorbable heart stents because they do not have to undergo a second procedure to remove the stent after it has served its purpose.

 To Understand More About this Research:  Request A Free Sample 

Top Players in the Absorbable Heart Stent Market 

Abbott Laboratories, Boston Scientific Corporation, Medtronic Plc, B. Braun Melsungen AG, and Biotronik, among others are some of the major players in the global Absorbable Heart Stent market.

In 2022, the top 10 players held around 85-90% of the global absorbable heart stent market. 

List of Key Companies Profiled:

• Abbott Laboratories
• Arterial Remodeling Technologies
• B. Braun Melsungen AG
• Biotronik
• Boston Scientific Corporation
• Elixir Medical Corporation
• Kyoto Medical Planning
• Medtronic
• Meril Life Sciences Pvt. Ltd
• Reva MedicalTerumo Medical Corporation
• Lepu Medical Technology Co.
• Other Prominent Players

Key Developments:

• July 2021: Medtronic plc announced the launch of the Prevail drug coated balloon (DCB) Catheter in Europe following CE (Conformité Européene) mark. The newest coronary Prevail DCB is used during percutaneous coronary intervention (PCI) procedures to treat narrowed or blocked coronary arteries in patients with coronary artery disease (CAD). The Prevail DCB utilizes a rapid absorption drug, paclitaxel to enable treatment of de novo lesions, small vessel disease, and in-stent restenosis (ISR).
• June 2021: Abbott announced its XIENCE family of stents received U.S. Food and Drug Administration (FDA) approval for one-month (as short as 28 days) DAPT labeling for high bleeding risk (HBR) patients in the U.S. In addition, XIENCE stents recently received CE Mark approval for DAPT as short as 28 days – giving XIENCE stents the shortest DAPT indication in the world.
• September 2021: BIOTRONIK announced that it received U.S. Food and Drug Administration (FDA) approval of its Orsiro Mission bioabsorbable polymer coronary drug-eluting stent system (BP-DES). The company also announced the first US implant and full commercial availability in the U.S. The Orsiro Mission DES features the same proprietary stent design and innovative bioabsorbable coating with controlled drug release as the Orsiro stent. Improvements to the new Orsiro Mission DES system include a re-engineered delivery system and a new deep embedding process to further improve deliverability including ‘best in class’ trackability and crossability.

Geographical Analysis

The North American region is expected to remain the largest consumer of absorbable heart stents around the globe due to a few key factors.Firstly, the region has a high prevalence of cardiovascular diseases, which leads to a large patient population requiring stent procedures. According to the American Heart Association, cardiovascular disease is the leading cause of death in the United States, with an estimated 655,000 deaths annually. Similarly, in Canada, cardiovascular disease is the second leading cause of death, accounting for approximately 20% of all deaths.

Secondly, the North American region has well-established healthcare infrastructure and high levels of healthcare spending, which enables patients to access the latest medical technologies, including absorbable heart stents. Thirdly, the region has a large number of key market players operating in the medical device industry, which has resulted in a high level of research and development in this field.

In terms of prevalence rates specifically in the US and Canada, data from the Centers for Disease Control and Prevention (CDC) indicate that approximately 18.2 million adults in the US have coronary artery disease, which is a common condition that can require stent procedures. Meanwhile, in Canada, it is estimated that approximately 1.6 million people have heart diseases.

On the other hand, Asia Pacific is projected to grow at the fastest CAGR growth due rapid growth in the demand for China and Australia on account increasing prevalence of CVD.

Segmental Overview

By Material

• Metallic Stents
• Polymer Stents

By Absorption Rate

• Slow absorption rate
• Fast absorption rate

By Application

• Coronary Artery Disease
• Peripheral Artery Disease

By End User

• Hospitals & Clinics
• Cardiovascular Centers
• Research Institutes & Organizations
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • The U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Poland
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa